keyword
MENU ▼
Read by QxMD icon Read
search

Gliosarcoma

keyword
https://www.readbyqxmd.com/read/29682024/adjuvant-radiation-therapy-and-temozolomide-in-gliosarcoma-is-it-enough-case-series-of-seven-patients
#1
Himanshu Srivastava, Abhinav Dewan, Surender Kumar Sharma, Preety Negi, Ajay Kumar Dewan, Sunil Pasricha, Krati Mehrotra
Objective: We present our experience of gliosarcoma (GSM) in oncology tertiary care center over the last 5 years. Materials and Methods: We carried out a retrospective analysis of seven patients with GSM diagnosed between April 2008 and December 2012. Demographic data, clinicopathological data, treatment strategies employed, details of recurrence, and survival patterns were reviewed. Results: The median age at diagnosis was 54 years, ranging between 34 and 63 years with a female predominance (57...
April 2018: Asian Journal of Neurosurgery
https://www.readbyqxmd.com/read/29564490/use-of-fet-pet-in-glioblastoma-patients-undergoing-neurooncological-treatment-including-tumour-treating-fields-initial-experience
#2
Garry Ceccon, Lazaros Lazaridis, Gabriele Stoffels, Marion Rapp, Manuel Weber, Tobias Blau, Phillip Lohmann, Sied Kebir, Ken Herrmann, Gereon R Fink, Karl-Josef Langen, Martin Glas, Norbert Galldiks
PURPOSE: We present our first clinical experience with O-(2-18 F-fluoroethyl)-L-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes. METHODS: We retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33-72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes...
March 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29504169/gliosarcoma-with-primitive-neuronal-chondroid-osteoid-and-ependymal-elements
#3
Yuka Yoshida, Munenori Ide, Hiroya Fujimaki, Nozomi Matsumura, Sumihito Nobusawa, Hayato Ikota, Hideaki Yokoo
A 51-year-old man presented with a 2-week history of malaise. MRI revealed a large solid and cystic lesion with ring enhancement measuring 6.5 cm in diameter in the right frontal lobe. Histologically, the tumor consisted of various components: diffuse growth of atypical astrocytic cells consistent with glioblastoma, fascicular proliferation of atypical spindle cells such as fibrosarcoma, clusters of primitive neuronal cells, and foci of ependymal cells. The sarcomatous component also focally exhibited chondroid and osteoid differentiation...
March 5, 2018: Neuropathology: Official Journal of the Japanese Society of Neuropathology
https://www.readbyqxmd.com/read/29487662/pineal-gliosarcoma-in-a-5-year-old-girl
#4
Ana María Granados, Camila Ospina, Stephania Paredes
The purpose of this paper is to report a rare case of a pediatric pineal gliosarcoma. Gliomas on the pineal region are uncommon, representing 0.4%-1% of all brain tumors. Furthermore, pediatric gliosarcomas are a very rare entity. We present a case of a 5-year-old girl, with a history of headache, vomiting, diplopia, and gait disturbances. A pineal tumor was found with pathology results consistent with a gliosarcoma. A total of 25 cases of pediatric gliosarcomas have been reported, none of them in pineal topography...
February 2018: Radiology Case Reports
https://www.readbyqxmd.com/read/29452330/atypical-teratoid-rhabdoid-tumor-after-in-vitro-fertilization-illustrative-case-report-and-systematic-literature-review
#5
REVIEW
Adomas Bunevicius, Algimantas Matukevicius, Vytenis Deltuva, Inga Gudinaviciene, Darius Pranys, Arimantas Tamasauskas
OBJECTIVE: In vitro fertilization (IVF) is increasingly used for the treatment of infertile couples worldwide. The association between IVF and cancer risk in offspring is conflicting. We present a case of atypical teratoid/rhabdoid tumor (AT/RT) in a girl conceived by IVF and present results of systematic review of literature of primary intracranial neoplasms diagnosed in children conceived by IVF. METHODS: A systematic review of literature was conducted on April 12, 2017, to identify previously published reports of intracranial brain tumors in patients conceived after IVF...
May 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29439667/impact-of-pkc%C3%AE%C2%B5-downregulation-on-autophagy-in-glioblastoma-cells
#6
Ewa Toton, Aleksandra Romaniuk, Natalia Konieczna, Johann Hofmann, Jan Barciszewski, Maria Rybczynska
BACKGROUND: Several efforts have been focused on identification of pathways involved in malignancy, progression, and response to treatment in Glioblastoma (GB). Overexpression of PKCε was detected in histological samples from GB, anaplastic astrocytoma, and gliosarcoma and is considered an important marker of negative disease outcome. In multiple studies on GB, autophagy has been shown as a survival mechanism during cellular stress, contributing to resistance against anti-cancer agents...
February 13, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29416795/treatment-associated-tp53-dna-binding-domain-missense-mutations-in-the-pathogenesis-of-secondary-gliosarcoma
#7
Margaret Pain, Huaien Wang, Eunjee Lee, Maya Strahl, Wissam Hamou, Robert Sebra, Jun Zhu, Raymund L Yong
Background: Gliosarcoma is a rare variant of glioblastoma (GBM) that exhibits frequent mutations in TP53 and can develop in a secondary fashion after chemoradiation of a primary GBM. Whether temozolomide (TMZ)-induced mutagenesis of the TP53 DNA-binding domain (DBD) can drive the pathogenesis of gliosarcoma is unclear. Methods: We identified a case of a primary GBM that rapidly progressed into secondary gliosarcoma shortly after chemoradiation was initiated. Bulk tumor was collected and gliomasphere cultures derived from both the pre- and post-treatment tumors...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29154508/primary-gliosarcoma-epidemiology-clinical-presentation-management-and-survival
#8
Ruichong Ma, Delia-Marina Alexe, Davide Boeris, Erlick Pereira
Gliosarcomas are malignant tumours of the central nervous system. As glioblastomas (GBM), they are treated in a similar fashion. However there is growing evidence to suggest that they may be a separate entity. Due to the rarity of primary gliosarcomas (PGS)Here we publish single centre data over a 14-year period, comprising possibly one of the biggest case series in the literature to our knowledge. The mean age at presentation was 59 years with male preponderance (1.75:1). The most common presenting symptoms were balance and mobility issues (61%), followed by headaches (50%) and visual problems (39%)...
November 20, 2017: Journal of Neurosurgical Sciences
https://www.readbyqxmd.com/read/29147435/gliosarcoma-in-young-adults-a-rare-variant-of-glioblastoma
#9
Neha Kakkar, Jaspreet Kaur, Gunjesh Kumar Singh, Pragya Singh, Fouzia Siraj, Ajay Gupta
Gliosarcoma is a rare central nervous system (CNS) malignancy. It is characterized by classical biphasic histological pattern with both glial and sarcomatous components, often seen in fifth and sixth decade of life. They are generally located in the supratentorial region. Due to its rarity, exact treatment recommendations are not available in literature. Since it is considered as a variant of glioblastoma multiforme (GBM), it is treated with surgery followed by adjuvant radiotherapy and temozolomide-based chemotherapy...
April 2017: World Journal of Oncology
https://www.readbyqxmd.com/read/29113409/phase-i-clinical-trial-of-axl1717-for-treatment-of-relapsed-malignant-astrocytomas-analysis-of-dose-and-response
#10
Robert Aiken, Magnus Axelson, Johan Harmenberg, Maria Klockare, Olle Larsson, Cecilia Wassberg
Purpose: Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation of preliminary anti-tumor efficacy. Patients and methods: Nine patients fulfilling the set criteria were enrolled. Eight had recurrent glioblastoma and one gliosarcoma. Patients were treated with an oral suspension of AXL1717 (215-400 mg bid) cycle-by-cycle in 35-day cycles (28 days bid and 7 days off). Patients with progressive disease and/or toxicity-related dose delay of more than 14 days were withdrawn...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29045711/the-endothelial-prostate-specific-membrane-antigen-is-highly-expressed-in-gliosarcoma-and-visualized-by-68ga-psma-11-pet-a-theranostic-outlook-for-brain-tumor-patients
#11
Marcus Unterrainer, Maximilian Niyazi, Viktoria Ruf, Peter Bartenstein, Nathalie L Albert
No abstract text is available yet for this article.
November 29, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29042753/functional-and-morphological-effects-of-diazepam-and-midazolam-on-tumor-vasculature-in-the-9l-gliosarcoma-brain-tumor-model-using-dynamic-susceptibility-contrast-mri-a-comparative-study
#12
Nuo Yan, Yuzhen Zheng, Cheng Yang
Antiangiogenic therapy attenuates tumor growth by reducing vascularization. Diazepam (DZP) and midazolam (MZL) have antiangiogenic properties in human umbilical vein endothelial cells. Thus, we investigated the antiangiogenic activity of DZP and MZL in the rat 9L gliosarcoma brain tumor model. The effect on tumor vasculature was evaluated using dynamic susceptibility contrast magnetic resonance imaging with gradient-echo (GE) and spin-echo (SE) to assess perfusion parameters, including cerebral blood volume (CBV), cerebral blood flow (CBF), mean transit time (MTT), and mean vessel diameter...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28967952/real-time-methylation-specific-polymerase-chain-reaction-for-mgmt-promoter-methylation-clinical-testing-in-glioblastoma-an-alternative-detection-method-for-a-heterogeneous-process
#13
Cristiane M Ida, Malinda L Butz, Robert B Jenkins, Jann N Sarkaria, Gaspar J Kitange, Caterina Giannini, Benjamin R Kipp
Objectives: To develop and evaluate a real-time methylation-specific polymerase chain reaction (RT-MSP) MGMT assay, with a particular focus on small biopsies and indeterminate testing results. Methods: We assessed formalin-fixed paraffin-embedded glioblastoma or gliosarcoma specimens (n = 641). A test-validation group (n = 51) with previously obtained reference laboratory (RL) results was used to determine performance characteristics of the RT-MSP assay. An indeterminate (equivocal) category was established for cases that could not be clearly classified as positive or negative...
October 1, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28904651/-primary-cerebral-gliosarcoma-about-two-cases-and-review-of-the-literature
#14
REVIEW
Mohamed Amine Azami, Iliass El Alami, Imane Bourhafour, Salwa Belhabib, Mohamed Oukabli, Abderrahmane Albouzidi
Gliosarcoma is a very rare brain tumor accounting for 1.8 -8% of all glial tumors. It has been classified by the World Health Organization as a variant of glioblastoma. It is a tumor with double glial and sarcomatous component. Patient's clinical picture is polymorphic, imaging data are evocative, diagnosis is based on histology. Treatment is always surgical. Prognosis is closely linked to the quality of resection. We here report two clinical cases with the aim of assessing the diagnostic, therapeutic and prognostic features of this rare entity...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28887206/reproducibility-and-relative-stability-in-magnetic-resonance-imaging-indices-of-tumor-vascular-physiology-over-a-period-of-24h-in-a-rat-9l-gliosarcoma-model
#15
Tavarekere N Nagaraja, Rasha Elmghirbi, Stephen L Brown, Lonni R Schultz, Ian Y Lee, Kelly A Keenan, Swayamprava Panda, Glauber Cabral, Tom Mikkelsen, James R Ewing
PURPOSE: The objective was to study temporal changes in tumor vascular physiological indices in a period of 24h in a 9L gliosarcoma rat model. METHODS: Fischer-344 rats (N=14) were orthotopically implanted with 9L cells. At 2weeks post-implantation, they were imaged twice in a 24h interval using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Data-driven model-selection-based analysis was used to segment tumor regions with varying vascular permeability characteristics...
December 2017: Magnetic Resonance Imaging
https://www.readbyqxmd.com/read/28812310/gliosarcoma-arising-from-oligodendroglioma-idh-mutant-and-1p-19q-codeleted
#16
Takayuki Yasuda, Masayuki Nitta, Takashi Komori, Tatsuya Kobayashi, Kenta Masui, Takashi Maruyama, Tatsuo Sawada, Yoshihiro Muragaki, Takakazu Kawamata
Herein, we present a rare case of gliosarcoma arising from oligodendroglioma, isocitrate dehydrogenase (IDH) mutant and 1p/19q codeleted. A 36-year-old man presented with a non-enhanced calcified abnormal lesion on the right frontal lobe. The patient underwent subtotal surgical resection, PAV chemotherapy (procarbazine, nimustine (ACNU) and vincristine), and fractionated radiotherapy with 50 Gy. The pathological diagnosis was oligodendroglioma, IDH mutant and 1p/19q codeleted, World Health Organization 2016 grade II...
February 2018: Neuropathology: Official Journal of the Japanese Society of Neuropathology
https://www.readbyqxmd.com/read/28776680/genistein-exerts-potent-antitumour-effects-alongside-anaesthetic-propofol-by-suppressing-cell-proliferation-and-nuclear-factor-%C3%AE%C2%BAb-mediated-signalling-and-through-upregulating-microrna-218-expression-in-an-intracranial-rat-brain-tumour-model
#17
Yuzhen Zheng, Haigen Liu, Yu Liang
OBJECTIVE: This study was implemented to evaluate the effect of genistein and propofol on intracranial tumour model. METHODS: Male Fischer 344 rats were subjected to intracranial implantation of 9L gliosarcoma cells. Genistein (100 or 200 mg/kg b.wt) was administered orally regularly from 3rd day after implantation to 25th day. Propofol (20 mg/kg; i.p.) was administered once every 5 days till 25th day and was administered 2 h after genistein. KEY FINDINGS: Human gliosarcoma cells (U251) exposed to genistein (12...
November 2017: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/28775171/gliosarcomas-with-the-braf-v600e-mutation-a-report-of-two-cases-and-review-of-the-literature
#18
REVIEW
Leiming Wang, Jian Sun, Zhuo Li, Li Chen, Yongjuan Fu, Lihong Zhao, Li Liu, Yukui Wei, Lianghong Teng, Dehong Lu
Gliosarcoma, which is regarded as a variant of glioblastoma, is a rare malignant neoplasm of the central nervous system. Both its sarcomatous component and glial component are reported to share significant clinical and genetic similarities. However, gliosarcomas are considered to be characterised by a lack of the BRAF V600E mutation. Here, we report two cases of gliosarcoma harbouring the BRAF V600E mutation, of which one case appears to have arisen de novo, while the other likely arose from ganglioglioma. Interestingly, the BRAF V600E mutation was detected only in the glial component in the first case, but was present in both the glial and the sarcomatous components in the recurrent gliosarcoma...
December 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28756069/gliosarcoma-in-septuagenarians-and-octogenarians-what-is-the-impact-of-adjuvant-chemoradiation
#19
Jacob Y Shin, Ja Kyoung Yoon, Aidnag Z Diaz
The objective of our study is to determine the impact of adjuvant chemoradiation on overall survival (OS) for gliosarcoma in septuagenarians and octogenarians. Data were extracted from the National Cancer Data Base (NCDB). Chi-square test, Kaplan-Meier method, and Cox regression models were employed in SPSS 23.0 (Armonk, NY: IBM Corp.) for data analyses. 210 patients with gliosarcoma who underwent resection were identified. 168 (80.0%) patients received adjuvant chemoradiation, and 42 (20.0%) received adjuvant RT alone...
November 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28748342/non-canonical-idh1-and-idh2-mutations-a-clonal-and-relevant-event-in-an-italian-cohort-of-gliomas-classified-according-to-the-2016-world-health-organization-who-criteria
#20
Michela Visani, Giorgia Acquaviva, Gianluca Marucci, Alexandro Paccapelo, Antonella Mura, Enrico Franceschi, Daniela Grifoni, Annalisa Pession, Giovanni Tallini, Alba A Brandes, Dario de Biase
According to the 2016 World Health Organization (WHO) classification of tumors of the central nervous system, assessment of exon 4 mutations in isocitrate dehydrogenase 1 or 2 genes (IDH1 or IDH2) is an essential step in the characterization of gliomas. The p.R132H mutation is the most frequent alteration in IDH genes, however other non-canonical IDH mutations can be identified. The aim of this study is to investigate in depth the prevalence of non-R132H IDH ("non-canonical") mutations in brain tumors classified according to the 2016 WHO scheme and their clonal distribution in neoplastic cells...
November 2017: Journal of Neuro-oncology
keyword
keyword
64102
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"